Stock Upgrades: Neurocrine Biosciences Shows Rising Relative StrengthInvestors Business Daily • 03/11/20
Neurocrine Biosciences Earns Membership In 95-Plus Composite Rating ClubInvestors Business Daily • 02/19/20
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/05/20
Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 01/09/20
Red-Hot Biotech Stocks Brace For Key Meeting — Here's What To ExpectInvestors Business Daily • 01/09/20
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for EpilepsyGlobeNewsWire • 12/02/19
Neurocrine Bounces Back With Authority, But Little Upside Appears Evident As New Year ApproachesSeeking Alpha • 11/20/19
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/05/19
Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)Zacks Investment Research • 11/01/19